Microbiome-targeted and global assay testing for laboratory medicine

The National Institutes of Health (NIH) intends to award a fixed priced purchase order for a one year base period and one (1) twelve month option period on a sole source basis to Metabolon, Inc., Morrisville, North Carolina, 27560, UEI: SBY5A7EK9PU3 for testing services needed to support a clinical research study. Metabolon offers microbiome-targeted and global assay testing not performed in the Clinical Center Department of Laboratory Medicine (DLM) laboratory. The primary objective of the study is to examine associations between diet and the gut microbiome. A secondary objective is examining the associations between the gut microbiome and changes in metabolites. The proposed vendor, Metabolon, Inc., specializes in the bioanalysis and data interpretation of metabolomics for the mechanistic understanding of biomarkers at a cellular level. Metabolon sets itself apart with superior analytical and bioinformatics technologies, which together produce high-quality data via a high-throughput workflow. Metabolon proprietary bioinformatics technology rapidly sorts through massive amounts of biochemical data, extracting only the significant information. These technologies, combined with rigorous QC processes, allow for the most comprehensive, high quality, and accurate metabolomics data to be rapidly transformed into knowledge that scientists can immediately put into action; a technology Metabolon calls, Precision Metabolomics. It is critical to put DLM study results into context, to compare the new testing data to the existing results from similar clinical trials that performed testing at Metabolon. Metabolon Inc. has unique qualifications in that it is the only company that offers Bile acids, and Short Chain Fatty Acids, and untargeted metabolomics on the combination of specimens for the study including stool and urine and plasma. Metabolon has also been cited in numerous publications within the research field that will allow DLM to make data comparisons during data analysis and interpretation. This acquisition is being conducted under the authority of the FAR Subpart 13.106-1(b)(i), Contracting officers may solicit from one source if the contracting officer determines that the circumstances of the contract action deem only one source reasonably available. The total dollar value of this purchase order shall not exceed the SAT at $250,000.00. Interested concerns capable of providing the same or similar products or services as described in this notice may submit a capability statement outlining their capabilities. Capability Statements must be received within the time set forth in this synopsis to be considered by the Government. A determination to compete this proposed contract based on responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. Each response should include the following Business Information: a. UEI. b. Company Name, address, POC, Phone and Email address c. Current GSA Schedules or NAICS codes appropriate to this Award. d. Type of Company (i.e., small business, 8(a), woman owned, hubZone, veteran owned, etc.) as validated in System for Award Management (SAM). All offerors must register on the SAM located at http://www.sam.gov/portal/SAM/#1 e. Capability Statement Comments to this announcement may be submitted to the Clinical Center, Office of Purchasing and Contracts, prior to the closing date specified in this announcement, electronically to the attention of Malinda Dehner, Contract Specialist, [email protected] by the due date and time marked in this notice.